RNS Number : 8728Z
Valereum PLC
07 March 2025

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

07/03/2025

Valereum Plc

("Valereum", "VLRM" or the "Company")

Deal Completion Update

Valereum Plc (AQSE: VLRM) provides an update on the £19 million subscription by Valereum Inc., and the £1 million subscription by the institutional investor, announced on 20 February 2025. Completion, initially expected on or around 4 March, has been extended to support the transaction, including relevant due diligence and receipt of source of funds and information required to satisfy KYC / AML laws.

The Board and DMC remain confident about the progress and expect completion in due course.

We will look to update the market when appropriate.

For more information, and the chance to have your questions directly answered by the management team, please head to our interactive investor hub via:Investor Hub. Here you will find all company news and additional content to further explain Valereum's strategy and products.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

Valereum Plc Peter Sekhon, Investor Relation Director Engage with the company directly	Tel: +44 7938 767319 Investor Hub
Stanford Capital Partners Bob Pountney/ Patrick Claridge	Tel: +44 023 3650 3650
AQSE Corporate Adviser **First Sentinel Corporate Finance** Brian Stockbridge / Gabrielle Cordeiro	Tel: +44 20 3855 5551

For more information, please visit the Company's website atwww.vlrm.com or to engage with the Valereum management team directly by asking questions, watching video summaries and seeing what other shareholders have to say.

Navigate to our Interactive Investor hub here: Sign Up

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFISVRIDIIE